Iotrizoic Acid

Iotrizoic Acid

SCHEMBL2111608

COCCOCCOCCOCCOCC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.58
MAPK1 P28482 1/20 0.58
NAMPT P43490 3/20 0.37
AKT1 P31749 1/20 0.37
OPRM1 P35372 3/20 0.34
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 2/20 0.33
KDM4C Q9H3R0 1/20 0.33
CYP2C19 P33261 1/20 0.33
HPGD P15428 1/20 0.31
CHEK1 O14757 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iotrizoic Acid SCHEMBL31409209 1.00 TSHR (0.58) TSHRMAPK1NAMPTAKT1OPRM1
Iotetric Acid SCHEMBL37863 0.94 TSHR (0.65) TSHRMAPK1KDM4ENPC1MAPT
Iotetric Acid SCHEMBL27748028 0.94 TSHR (0.65) TSHRMAPK1KDM4ENPC1MAPT
Iotroxic Acid SCHEMBL38038 0.94 TSHR (0.65) TSHRMAPK1KDM4ENPC1MAPT
Iotroxic Acid SCHEMBL27729545 0.94 TSHR (0.65) TSHRMAPK1KDM4ENPC1MAPT
SCHEMBL28816554 0.87 MAPK1 (0.67) TSHRMAPK1MAPTSMN1; SMN2LMNA
Ioglycamic Acid SCHEMBL433485 0.87 TSHR (0.70) TSHRMAPK1KDM4ENPC1MAPT
Ioglycamic Acid SCHEMBL29881458 0.87 TSHR (0.70) TSHRMAPK1KDM4ENPC1MAPT
Iotranic Acid SCHEMBL2109613 0.83 TSHR (0.74) TSHRMAPK1NPC1RAB9ALMNA
Iodoxamic Acid SCHEMBL29397252 0.83 TSHR (0.74) TSHRMAPK1NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-0703790-B1 IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS BRACCO SPA (IT) 2000-08-16 EP claimed
US-5660814-A Iodinated paramagnetic chelates, and their use as contrast agents DIBRA S.P.A. (IT) 1997-08-26 US claimed
EP-0703790-A1 IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS BRACCO S.p.A. (IT) 1996-04-03 EP claimed
WO-1994027644-A1 IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS BRACCO S.P.A. (IT) 1994-12-08 WO claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 US disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US disclosed
US-20140154313-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2014-06-05 US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
US-5660814-A Iodinated paramagnetic chelates, and their use as contrast agents DIBRA S.P.A. (IT) 1997-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 TSHR 1871/4885MAPK1 4783/4885NAMPT 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.